Related Experiment Videos

Pneumococcal vaccination. Controversies and opportunities.

J S Spika1, D S Fedson, R R Facklam

  • 1Bureau of Communicable Disease Epidemiology, Laboratory Centre for Disease Control, Ottawa, Ontario, Canada.

Summary

Pneumococcal infections cause significant illness and death, but immunization with the 23-valent pneumococcal vaccine is cost-effective for high-risk individuals. Improved strategies are needed to increase vaccination rates among eligible populations.

Related Concept Videos